• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    These Emerging Companies Are Racing Toward Major Catalysts

    6/23/26 11:11:05 AM ET
    $NTHI
    $BOLD
    $BLZE
    $HSCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTHI alert in real time by email

    DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.

    NeOnc Technologies Approaches Major Clinical Catalyst

    NeOnc Technologies (NASDAQ:NTHI) has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase 2 studies, while also establishing a pathway for pediatric development in recurrent and progressive high-grade gliomas.

    The development significantly expands NeOnc's international clinical footprint and follows the company's previously announced UAE authorization for its NEO212 program. The broader authorization potentially allows parallel advancement of multiple development stages while complementing ongoing U.S. regulatory progress.

    Investors appear particularly focused on the company's upcoming NEO100-01 Phase 2a readout, which NeOnc expects to report by the end of July 2026. NEO100 already holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations, and management has indicated that positive data could support discussions involving additional regulatory pathways.

    High-grade gliomas remain among the most aggressive and difficult-to-treat brain cancers. NeOnc's intranasal delivery platform is designed to bypass the blood-brain barrier through non-invasive administration, a characteristic that differentiates the program from many traditional CNS treatment approaches. As the anticipated data release approaches, investors will be watching closely for evidence supporting further clinical advancement.

    Boundless Bio Reinvents Itself Through Transformational Merger

    Boundless Bio (NASDAQ:BOLD) announced a major strategic shift through its proposed merger with privately held Serapha Bio, creating a new publicly traded company focused on gene-editing therapies for Alpha-1 Antitrypsin Deficiency (AATD).

    The transaction is accompanied by approximately $230 million in committed financing from a syndicate led by RTW Investments and RA Capital Management, providing what the companies believe will be sufficient funding into the second half of 2029. The financing is expected to support Phase 2 completion and Phase 3 initiation for Serapha's lead candidate, SERP-01.

    SERP-01 is an investigational in vivo base-editing therapy designed to correct the SERPINA1 E342K mutation responsible for severe forms of AATD. The therapy aims to simultaneously address both liver and lung manifestations of the disease through a single administration by restoring functional alpha-1 antitrypsin production while reducing toxic protein accumulation.

    The transaction also highlights continued investor enthusiasm surrounding next-generation genetic medicines. With backing from prominent healthcare investors and a planned Nasdaq listing under the proposed ticker "AATD," the combined company enters the public markets with substantial capital resources and a focused development strategy targeting a significant unmet medical need.

    $335 Million AI Deal Ignites Backblaze as Data Storage Demand Explodes

    Backblaze (NASDAQ:BLZE) announced a five-year, multi-exabyte data storage agreement valued at approximately $335 million with CoreWeave, one of the fastest-growing AI cloud infrastructure providers in the market. The agreement positions Backblaze as a key storage provider supporting portions of CoreWeave's managed storage infrastructure as demand for AI computing capacity continues expanding globally.

    The partnership underscores a rapidly evolving reality within the AI ecosystem: compute power alone is no longer enough. Every stage of the AI lifecycle, from data preparation and model training to checkpointing, inference, and long-term storage, depends on the efficient movement and management of vast datasets. As organizations race to deploy increasingly sophisticated AI applications, the ability to store, retrieve, and manage data at scale has become a strategic competitive advantage.

    Under the agreement, Backblaze will provide HDD-based storage capacity supporting CoreWeave AI Object Storage, helping optimize data placement across performance tiers while preserving high-performance resources for the most demanding AI workloads. The integration allows customers to access expanded storage capabilities without modifying existing applications, potentially simplifying adoption for enterprises already operating within the CoreWeave ecosystem.

    Fortitude Mining Targets Public Markets Through HeartSciences Merger

    HeartSciences (NASDAQ:HSCS) announced a proposed business combination with Fortitude Mining Holdings, a digital asset mining platform focused primarily on Zcash.

    Upon closing, the combined company is expected to operate under the Fortitude name and trade under the proposed Nasdaq ticker "TUDE." Existing Fortitude owner Digital Currency Group is expected to hold approximately 95% of the combined company.

    Fortitude's model differs from many traditional mining operations through its emphasis on "venture mining," which focuses on identifying and scaling high-conviction Proof-of-Work opportunities. The company currently maintains a significant presence within the Zcash ecosystem and operates a vertically integrated infrastructure platform that includes power assets, mining operations, and data-center capacity.

    The transaction reflects ongoing consolidation and evolution within digital asset markets as infrastructure-focused operators seek broader access to public capital. As institutional participation in digital assets continues developing, investors may increasingly focus on mining companies with differentiated operational models and scalable infrastructure footprints.

    About 24/7 Market News

    In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

    This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.  For the full disclosure, please visit: https://go.247marketnews.com/nthi-disclosure/

    For further information, please visit 247marketnews.com.

    Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication.  Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

    CONTACT:

    24/7 Market News

    Editor@247marketnews.com

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.



    Get the next $NTHI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTHI
    $BOLD
    $BLZE
    $HSCS

    CompanyDatePrice TargetRatingAnalyst
    Backblaze Inc.
    $BLZE
    6/23/2026Underperform → Mkt Perform
    William Blair
    Backblaze Inc.
    $BLZE
    6/23/2026$16.00Hold → Buy
    Craig Hallum
    NeOnc Technologies Holdings Inc.
    $NTHI
    5/19/2026$13.00Buy
    Alliance Global Partners
    NeOnc Technologies Holdings Inc.
    $NTHI
    5/18/2026$20.00Buy
    Maxim Group
    NeOnc Technologies Holdings Inc.
    $NTHI
    4/24/2026$15.00Buy
    BTIG Research
    Backblaze Inc.
    $BLZE
    3/23/2026Outperform → Underperform
    William Blair
    Backblaze Inc.
    $BLZE
    2/24/2026$4.50Buy → Hold
    Craig Hallum
    Backblaze Inc.
    $BLZE
    6/24/2025$7.00Mkt Outperform
    Citizens JMP
    More analyst ratings

    $NTHI
    $BOLD
    $BLZE
    $HSCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Three Biotechs Deliver Catalysts to Watch

    DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ:NTHI), Ernexa Therapeutics (NASDAQ:ERNA), and VivoSim Labs (NASDAQ:VIVS) highlight three distinct pathways to potential value creation. NeOnc Technologies NeOnc Technologies (NASDAQ:NTHI) announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, NEO212, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other central nervous system cancers. Rather than proceeding with its scheduled Type B

    7/15/26 10:42:42 AM ET
    $NTHI
    $ERNA
    $VIVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

    CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today announced that it has received written feedback from the U.S. Food and Drug Administration ("FDA") regarding the chemistry, manufacturing and controls ("CMC") development program for NEO212, the Company’s novel temozolomide-perillyl alcohol conjugate. The written feedback was provided in advance of a Type B End-of-Phase 1 meeting scheduled for July 9, 2026. FDA’s preliminary comments expressly provided NeOnc the option to cancel the meeting i

    7/15/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Backblaze to Announce Second Quarter 2026 Results on August 3, 2026

    Backblaze, Inc. (NASDAQ:BLZE), the high-performance cloud storage platform for the AI era, will report financial results for its second quarter ending June 30, 2026 on Monday, August 3, 2026 after market close. Following the release of results, Backblaze will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) on August 3, 2026 to discuss the results. Attend the webcast: https://events.q4inc.com/attendee/704175018 Register to listen by phone: https://events.q4inc.com/analyst/704175018?pwd=29EpzfWI Phone registrants will receive dial-in information via email. An archive of the webcast will be available shortly after its completion on the Investor Relations page of the

    7/13/26 4:31:00 PM ET
    $BLZE
    Computer Software: Prepackaged Software
    Technology

    $NTHI
    $BOLD
    $BLZE
    $HSCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tang Kevin bought $11,866 worth of shares (4,863 units at $2.44) (SEC Form 4)

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    7/21/26 7:38:58 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Tang Kevin bought $155,646 worth of shares (63,969 units at $2.43) (SEC Form 4)

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    7/16/26 8:10:50 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Tang Kevin bought $222,070 worth of shares (91,585 units at $2.42) (SEC Form 4)

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    7/13/26 7:06:11 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    $BOLD
    $BLZE
    $HSCS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tang Kevin bought $11,866 worth of shares (4,863 units at $2.44) (SEC Form 4)

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    7/21/26 7:38:58 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Tang Kevin bought $155,646 worth of shares (63,969 units at $2.43) (SEC Form 4)

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    7/16/26 8:10:50 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Tang Kevin bought $222,070 worth of shares (91,585 units at $2.42) (SEC Form 4)

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    7/13/26 7:06:11 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    $BOLD
    $BLZE
    $HSCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Backblaze upgraded by William Blair

    William Blair upgraded Backblaze from Underperform to Mkt Perform

    6/23/26 2:05:43 PM ET
    $BLZE
    Computer Software: Prepackaged Software
    Technology

    Backblaze upgraded by Craig Hallum with a new price target

    Craig Hallum upgraded Backblaze from Hold to Buy and set a new price target of $16.00

    6/23/26 12:20:11 PM ET
    $BLZE
    Computer Software: Prepackaged Software
    Technology

    Alliance Global Partners initiated coverage on NeOnc Technologies Holdings with a new price target

    Alliance Global Partners initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $13.00

    5/19/26 8:31:51 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    $BOLD
    $BLZE
    $HSCS
    SEC Filings

    View All

    SEC Form DEFA14A filed by HeartSciences Inc.

    DEFA14A - HeartSciences Inc. (0001468492) (Filer)

    7/22/26 4:55:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    7/15/26 9:15:28 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by HeartSciences Inc.

    DEFA14A - HeartSciences Inc. (0001468492) (Filer)

    7/10/26 5:02:28 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $NTHI
    $BOLD
    $BLZE
    $HSCS
    Leadership Updates

    Live Leadership Updates

    View All

    Backblaze Brings AI Data Storage Expertise to RAISE Summit

    Backblaze sponsors RAISE Summit; CEO Gleb Budman joins panel on sovereign cloud strategy and judges world's largest AI startup competitionBackblaze (NASDAQ:BLZE), the high-performance cloud storage platform for the AI era, today announced its participation as a sponsor of RAISE Summit 2026 taking place July 8–9, 2026, at Le Carrousel du Louvre in Paris, France. Backblaze will confront the next AI infrastructure bottleneck: where data lives, how fast it moves, and what it costs to access. As AI-native enterprises and neocloud operators race to build sovereign, AI-ready infrastructure, Backblaze arrives at RAISE with expertise in the data foundations these businesses need – already supporting

    7/7/26 9:00:00 AM ET
    $BLZE
    Computer Software: Prepackaged Software
    Technology

    Backblaze Appoints Anuj Kumar as Chief Revenue Officer

    Company strengthens go-to-market leadership as AI workloads drive new storage demand Backblaze, Inc. (NASDAQ:BLZE), the high-performance cloud storage platform for the AI era, today announced the appointment of Anuj Kumar as Chief Revenue Officer. Kumar brings more than two decades of experience scaling cloud revenue organizations at enterprise infrastructure companies — most notably driving NetApp's worldwide cloud business during a period of significant growth. He joins Backblaze as Backblaze advances its go-to-market transformation and AI adoption drives a new phase of infrastructure demand. The appointment follows a period of accelerated momentum for Backblaze's B2 Cloud Storage bus

    4/13/26 9:00:00 AM ET
    $BLZE
    Computer Software: Prepackaged Software
    Technology

    NeOnc Technologies Appoints David Choi as Chief Accounting Officer

    CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, has appointed David Choi as Chief Accounting Officer. In this role, Mr. Choi is responsible for overseeing the Company's accounting, financial reporting, internal controls, and corporate governance functions as NeOnc advances its clinical-stage biotechnology platform and expands its global operations. "David's extensive expertise in technical accounting and financial reporting for public companies comes at a pivotal time for NeOnc," said

    3/13/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    $BOLD
    $BLZE
    $HSCS
    Financials

    Live finance-specific insights

    View All

    Backblaze to Announce Second Quarter 2026 Results on August 3, 2026

    Backblaze, Inc. (NASDAQ:BLZE), the high-performance cloud storage platform for the AI era, will report financial results for its second quarter ending June 30, 2026 on Monday, August 3, 2026 after market close. Following the release of results, Backblaze will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) on August 3, 2026 to discuss the results. Attend the webcast: https://events.q4inc.com/attendee/704175018 Register to listen by phone: https://events.q4inc.com/analyst/704175018?pwd=29EpzfWI Phone registrants will receive dial-in information via email. An archive of the webcast will be available shortly after its completion on the Investor Relations page of the

    7/13/26 4:31:00 PM ET
    $BLZE
    Computer Software: Prepackaged Software
    Technology

    Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets

    Combined company expected to operate under the Fortitude brand and to trade on Nasdaq under the ticker symbol "TUDE"; transaction expected to close in H2 2026 Upon completion of the transaction, Fortitude believes it will be the first publicly traded venture mining platform with a track record of identifying high-conviction, early-stage Proof-of-Work opportunities Fortitude Mining Holdings, Inc. ("Fortitude"), a vertically-integrated digital asset mining platform anchored in Zcash, and HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences"), an AI-powered medical technology company, today announced that they have entered into a definitive merger agreement to combine in an all-stock transacti

    6/23/26 7:30:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement

    Combined company to operate as Serapha Bio and to advance Serapha’s potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha’s lead program SERP-01 targets the SERPINA1 E342K (PiZZ) mutation, with proof-of-concept data demonstrating restoration of serum AAT to normal levels Concurrent $230 million private placement co-led by RTW Investments and RA Capital Management, with participation from syndicate of top healthcare investors and mutual funds Companies to hold joint webcast on Tuesday, June 23, 2026 at 8:30 a.m. ET SAN DIEGO and NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Boundless Bio, Inc. (NASDAQ:BOLD) and Serapha Bio, Inc., a privately held

    6/23/26 7:30:00 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    $BOLD
    $BLZE
    $HSCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Boundless Bio Inc.

    SC 13D - Boundless Bio, Inc. (0001782303) (Subject)

    10/29/24 6:32:08 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Backblaze Inc. (Amendment)

    SC 13G/A - Backblaze, Inc. (0001462056) (Subject)

    2/14/24 6:23:57 PM ET
    $BLZE
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Backblaze Inc. (Amendment)

    SC 13G/A - Backblaze, Inc. (0001462056) (Subject)

    2/14/24 6:22:04 PM ET
    $BLZE
    Computer Software: Prepackaged Software
    Technology